Scott N. Boyle
CIK: 0001913897
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
C4 Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (14 total)
- Feb 14, 2026CCCC
C4 Therapeutics, Inc.
Tax Payment(F)Direct7.3K shares at avg. $1.89$14K - Feb 14, 2026CCCC
C4 Therapeutics, Inc.
Exercise(M)Direct21K shares- - Feb 13, 2026CCCC
C4 Therapeutics, Inc.
Award(A)Direct200K shares- - Feb 13, 2026CCCC
C4 Therapeutics, Inc.
Exercise(M)Direct5K shares- - Feb 13, 2026CCCC
C4 Therapeutics, Inc.
Tax Payment(F)Direct1.7K shares at avg. $1.89$3K - Feb 18, 2025CCCC
C4 Therapeutics, Inc.
Sale(S)Direct669 shares at avg. $3.15$2K - Feb 14, 2025CCCC
C4 Therapeutics, Inc.
Sale(S)Direct490 shares at avg. $3.15$2K - Feb 14, 2025CCCC
C4 Therapeutics, Inc.
Award(A)Direct56.5K shares- - Feb 14, 2025CCCC
C4 Therapeutics, Inc.
Tax Payment(F)Direct2.4K shares at avg. $3.18$8K - Feb 13, 2025CCCC
C4 Therapeutics, Inc.
Tax Payment(F)Direct1.7K shares at avg. $3.20$6K - Nov 7, 2024CCCC
C4 Therapeutics, Inc.
Exercise(M)Direct3.8K shares- - Nov 7, 2024CCCC
C4 Therapeutics, Inc.
Tax Payment(F)Direct1.1K shares at avg. $6.04$7K - Sep 16, 2024CCCC
C4 Therapeutics, Inc.
Exercise(M)Direct2.3K shares- - Sep 16, 2024CCCC
C4 Therapeutics, Inc.
Tax Payment(F)Direct661 shares at avg. $6.36$4K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 14, 2026 | CCCC C4 Therapeutics, Inc. | Tax Payment(F) | 7,269 | $1.89 | $13,738 | Direct |
| Feb 14, 2026 | CCCC C4 Therapeutics, Inc. | Exercise(M) | 20,950 | - | $0 | Direct |
| Feb 13, 2026 | CCCC C4 Therapeutics, Inc. | Award(A) | 200,000 | - | $0 | Direct |
| Feb 13, 2026 | CCCC C4 Therapeutics, Inc. | Exercise(M) | 5,000 | - | $0 | Direct |
| Feb 13, 2026 | CCCC C4 Therapeutics, Inc. | Tax Payment(F) | 1,735 | $1.89 | $3,279 | Direct |
| Feb 18, 2025 | CCCC C4 Therapeutics, Inc. | Sale(S) | 669 | $3.15 | $2,107 | Direct |
| Feb 14, 2025 | CCCC C4 Therapeutics, Inc. | Sale(S) | 490 | $3.15 | $1,544 | Direct |
| Feb 14, 2025 | CCCC C4 Therapeutics, Inc. | Award(A) | 56,500 | - | - | Direct |
| Feb 14, 2025 | CCCC C4 Therapeutics, Inc. | Tax Payment(F) | 2,368 | $3.18 | $7,530 | Direct |
| Feb 13, 2025 | CCCC C4 Therapeutics, Inc. | Tax Payment(F) | 1,735 | $3.20 | $5,552 | Direct |
| Nov 7, 2024 | CCCC C4 Therapeutics, Inc. | Exercise(M) | 3,750 | - | $0 | Direct |
| Nov 7, 2024 | CCCC C4 Therapeutics, Inc. | Tax Payment(F) | 1,102 | $6.04 | $6,656 | Direct |
| Sep 16, 2024 | CCCC C4 Therapeutics, Inc. | Exercise(M) | 2,250 | - | $0 | Direct |
| Sep 16, 2024 | CCCC C4 Therapeutics, Inc. | Tax Payment(F) | 661 | $6.36 | $4,204 | Direct |
1-14 of 14 transactions
About Boyle Scott N
Boyle Scott N (SEC CIK 0001913897) files insider reports with the SEC as Chief Business Officer of C4 Therapeutics, Inc. (CCCC).
Signal8 holds 4 ownership filings by Boyle Scott N, all Form 4s, filed between Sep 17, 2024 and Feb 18, 2026. Those filings report 14 transactions, from Sep 16, 2024 to Feb 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Boyle Scott N's filings is in WATERTOWN, MA.
Recent filings by Boyle Scott N
- Feb 14, 2026: Tax withholding of CCCC shares (Form 4, code F).
- Feb 14, 2026: Option exercise of CCCC shares (Form 4, code M).
- Feb 13, 2026: Grant or award of CCCC shares (Form 4, code A).
- Feb 13, 2026: Option exercise of CCCC shares (Form 4, code M).
- Feb 13, 2026: Tax withholding of CCCC shares (Form 4, code F).
Other insiders filing for C4 Therapeutics, Inc. (CCCC)
- Anderson Kenneth Carl, Director
- GROGAN DONNA ROY, Director
- Adams Kendra, Chief Financial Officer
- REYNO LEONARD, Chief Medical Officer
- Hughes Owen, Director
- Hoerter Steven L., Director